Buchumschlag

Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real‐World Analysis in Japanese Patients

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Tomoyo Yasuda, Mio Yumura, Azusa Hamasaki, Tongyi Fei, Takashi Kubo, Hitoshi Ichikawa, Takashi Kohno, Kuniko Sunami
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Cancer Science
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Leveraging non‐coding regions to guarantee the accuracy of small‐sized panel‐based tumor mutational burden estimates
von: Takahiro Nishino, et al.
Veröffentlicht: (2024)

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden‐High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment
von: Yugo Kai, et al.
Veröffentlicht: (2026)

Real‐World Comparison of Gene‐Matched vs. Non‐Gene‐Matched Therapy Outcomes Using Integrated Genomic and Clinical Data
von: Taisuke Ishii, et al.
Veröffentlicht: (2025)

Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
von: Lisa Shigematsu, et al.
Veröffentlicht: (2025)

Cross‐individual cancer transmission to children during the gestational and perinatal periods
von: Ayumu Arakawa, et al.
Veröffentlicht: (2024)

Real‐World Treatment Patterns Before and After Metastatic Castration–Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital‐Based, Multicenter Database
von: Masaki Shiota, et al.
Veröffentlicht: (2026)

Identification of barriers to implementation of precision oncology in patients with rare cancers
von: Shigemasa Takamizawa, et al.
Veröffentlicht: (2024)

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study
von: Junya Arima, et al.
Veröffentlicht: (2025)

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets
von: Zhaohui Liao Arter, et al.
Veröffentlicht: (2025)

Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations
von: Derek Effiom, et al.
Veröffentlicht: (2025)

Nationwide Real‐World Usage of Blood‐Based (Liquid) Biomarker Testing in Japan
von: Yasushi Yatabe, et al.
Veröffentlicht: (2025)

Cholesterol synthesis is essential for the growth of liver metastasis‐prone colorectal cancer cells
von: Kumiko Taniguchi, et al.
Veröffentlicht: (2024)

Prospective Registry and Meta‐Analysis of Particle Therapy for Hepatocellular Carcinoma: Clinical Outcomes and Real‐World Impact
von: Masashi Mizumoto, et al.
Veröffentlicht: (2026)

Understanding the Burden of Care for Children With Pediatric Solid Tumors
von: Julie M. Thamby, et al.
Veröffentlicht: (2026)

A Systematic Review and Meta‐Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours
von: Aijia Meng, et al.
Veröffentlicht: (2026)

Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
von: Yutaro Nagano, et al.
Veröffentlicht: (2026)

Real‐World Data on the p. Gly17Val RHOA Mutation in Diagnosing T Follicular Helper Cell Lymphomas
von: Yuri Tsuboi, et al.
Veröffentlicht: (2025)

Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors
von: Zoë L. Hawking, et al.
Veröffentlicht: (2025)

Somatic Mutations of Thymic Epithelial Tumors Identified in the Prospective THYMOGENE Trial
von: Eleonora Pardini, et al.
Veröffentlicht: (2025)

Therapeutic Indications of Pembrolizumab in Eight Common Cancers: Current Evidence and Future Directions
von: Raghed Mansour, et al.
Veröffentlicht: (2025)

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
von: Kun Wang, et al.
Veröffentlicht: (2025)

Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study
von: Masahiro Tsuboi, et al.
Veröffentlicht: (2024)

TRAF7 ‐Mutated Fibromyxoid Spindle Cell Tumor of Bone: An Osseous Case Expanding the Spectrum of TRAF7 ‐Mutated Tumors With Over 20 Years Clinical Follow‐Up
von: Laura M. Warmke, et al.
Veröffentlicht: (2026)

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE ‐522 Japan Subgroup Analysis
von: Masato Takahashi, et al.
Veröffentlicht: (2026)

Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach
von: Zhiying Gao, et al.
Veröffentlicht: (2025)

Constructing Tumor Cellular Cluster Models and Their Evolutionary Dynamics to Decode Tumor Evolution
von: Haili Qian, et al.
Veröffentlicht: (2026)

Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan
von: Satoshi Miyamoto, et al.
Veröffentlicht: (2025)

Cross‐Sectional Analysis of Metabolic Tumor Burden Detected by F‐18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer
von: Recep Halit Tokac, et al.
Veröffentlicht: (2025)

Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node‐Positive Breast Cancer: Real World Data
von: Danyang Ji, et al.
Veröffentlicht: (2025)

NF1 Mutated Gastrointestinal Stromal Tumors With Coamplification of MDM2 and MYC
von: Xinyang Chen, et al.
Veröffentlicht: (2025)

Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer
von: Rui Kitadai, et al.
Veröffentlicht: (2025)

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago‐gastric Diseases (PROCEED): A single‐arm phase 2 trial
von: Pooja Karukonda, et al.
Veröffentlicht: (2025)

T‐Cell Immunoglobulin and Mucin Domain 1 (Tim1) as a Prognostic Factor Associated With Therapeutic Resistance in Human Breast Carcinoma
von: Mio Yamaguchi-Tanaka, et al.
Veröffentlicht: (2026)

Allelic Imbalance and Chromothripsis Lead to Diversity in Japanese Tumor Genomes With Whole‐Genome Duplication
von: Keiichi Hatakeyama, et al.
Veröffentlicht: (2025)

Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis
von: Mio Takahashi, et al.
Veröffentlicht: (2025)

Germline BRCA1‐Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long‐Term Survival
von: Tomohiro Kubo, et al.
Veröffentlicht: (2024)

Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients
von: Shuhei Kamada, et al.
Veröffentlicht: (2025)

Patterns of Treatment and Real‐World Outcomes of Patients With Non‐small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
von: Geoffrey Liu, et al.
Veröffentlicht: (2025)

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis
von: Caleb Q. Ashbrook, et al.
Veröffentlicht: (2026)

Tumor‐derived lactic acid promotes acetylation of histone H3K27 and differentiation of IL‐10‐producing regulatory B cells through direct and indirect signaling pathways
von: Satoshi Muraoka, et al.
Veröffentlicht: (2024)